Alnylam Pharmaceuticals | ALNY - Stock


Alnylam Pharmaceuticals reported $200.15M in Stock for its fiscal quarter ending in March of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 31.57M 3.1M Mar/2026
Agios Pharmaceuticals USD 35.09M 2.17M Mar/2026
Alnylam Pharmaceuticals USD 200.15M 117.43M Mar/2026
Amgen USD 6.19B 39M Mar/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
BioCryst Pharmaceuticals USD 5.98M 587K Mar/2026
BioMarin Pharmaceutical USD 1.27B 25.66M Mar/2026
Incyte USD 115.62M 14.56M Mar/2026
Ionis Pharmaceuticals USD 5.56M 4.49M Mar/2026
Moderna USD 146M 7M Mar/2026
Neurocrine Biosciences USD 64.5M 4.5M Mar/2026
Novartis USD 6.29B 135M Mar/2026
PTC Therapeutics USD 75.57M 4.08M Mar/2026
Regeneron Pharmaceuticals USD 3.1B 97.2M Mar/2026
Sanofi EUR 23.5B 812M Mar/2026
Sarepta Therapeutics USD 1B 86.37M Mar/2026
Takeda JPY 1.41T 107.71B Dec/2025
Ultragenyx Pharmaceutical USD 55M 3M Mar/2026
Vertex Pharmaceuticals USD 1.77B 79.9M Mar/2026